Physician profile
Brigitte N Sledge
NPI 1285139063
$2,466.91
in general payments reported to CMS, 2019-2025
18 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $601 · 2023: $522 · 2024: $483 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.60 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $366.35 | 2025 | Bimzelx |
| Lilly USA, LLC | $278.40 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $277.22 | 2022-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $250.87 | 2023-2025 | Otezla, Enbrel |
| Janssen Biotech, INC. | $218.87 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $199.59 | 2022-2025 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $174.79 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $149.42 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $147.52 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $92.53 | 2022-2024 | |
| Galderma Laboratories, L.P. | $80.59 | 2025 | Nemluvio |
| Incyte Corporation | $68.27 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $41.92 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.23 | 2023 | Jublia |
| Pfizer INC. | $27.98 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $26.21 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.22 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $10.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigitte Sledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.